Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome

Fabio M. Simoes de Souza¹*, Nicolas Busquet¹-³*, Megan Blatner², Kenneth N. Maclean³ & Diego Restrepo¹

Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome

Fabio M. Simoes de Souza¹*, Nicolas Busquet¹-³*, Megan Blatner², Kenneth N. Maclean³ & Diego Restrepo¹

1Cell and Developmental Biology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A., 2University of Colorado Denver, Denver, CO, U.S.A., 3Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A.

Down syndrome (DS) is the most common form of congenital intellectual disability. Although DS involves multiple disturbances in various tissues, there is little doubt that in terms of quality of life cognitive impairment is the most serious facet and there is no effective treatment for this aspect of the syndrome. The Ts65Dn mouse model of DS recapitulates multiple aspects of DS including cognitive impairment. Here the Ts65Dn mouse model of DS was evaluated in an associative learning paradigm based on olfactory cues. In contrast to disomic controls, trisomic mice exhibited significant deficits in olfactory learning. Treatment of trisomic mice with the acetylcholinesterase inhibitor galantamine resulted in a significant improvement in olfactory learning. Collectively, our study indicates that olfactory learning can be a sensitive tool for evaluating deficits in associative learning in mouse models of DS and that galantamine has therapeutic potential for improving cognitive abilities.

Down syndrome (DS) was first described by the English physician John Langdon Down in 1866. It was subsequently shown that this condition is caused by trisomy of chromosome (Chr) 21, which in the majority of cases, is present in its entirety and is of maternal origin (reviewed in¹). Although DS involves multiple disturbances in a relatively wide range of tissues there is little doubt that in terms of quality of life of the person and parents, relatives and caretakers, cognitive impairment is the most serious aspect of this syndrome. Mental retardation is evident as lower verbal and mental performance in the mild to moderate range and individuals with DS show distinct delay in language development, deficits in auditory sequential processing and verbal short-term memory¹. In addition to these impairments, as children with DS grow into adults, they frequently incur an age-associated neuronal loss, reminiscent of Alzheimer’s disease⁴-⁷. By the fourth decade, most DS adults show signs of early onset Alzheimer’s, with the first presentation of neurofibrillary tangles and neuritic plaques in regions associated with learning and memory⁴,⁸-¹⁰.

The Ts65Dn mouse is a segmental trisomy mouse model of DS containing a third copy of the distal region of mouse Chr 16 that contains 94 genes orthologous to the DS critical region of human Chr 21¹¹. Ts65Dn mice survive to adulthood and recapitulate multiple biochemical, morphological and transcriptional aspects of DS as it occurs in humans¹¹-¹³ and has become an informative animal model of this syndrome (reviewed in¹⁴). Although Ts65Dn mice perform similarly to disomic controls in visual placing, balance, prehensile reflex, traction on a horizontal bar, motor coordination¹⁵, and olfaction orienting¹⁶, neural cognitive deficits¹⁷-¹⁹, motor and behavioral abnormalities have been noted in these mice²⁰-²². Deficits in spatial learning and memory have been especially prominent with significant impairment in both Morris water maze and radial maze performance compared to disomic littermate controls²¹,²³-²⁵. Other behavioral abnormalities include locomotor hyperactivity and stereotypic behavior²⁴,²⁵. We wanted to avoid the potential confound between motor deficits and performance in spatial learning tasks, and also estimate learning using ethologically relevant cues.

Mice are macrosmatic animals, and use their acute sense of smell in many aspects of their lives that relate to learning and memory, from communicating with conspecifics, finding food to avoiding predators²⁷,²⁸. In spite of the importance of this sensory modality, few studies have dealt with olfactory-based tasks in Ts65Dn mice²⁶. In this study, we report the first investigation of associative olfactory learning performance in trisomic Ts65Dn mice and disomic littermates in a computerized go-no-go odor discrimination task. We used a complementary hidden peanut butter finding test to assess whether changes in sensory-motor abilities could affect odor responses.
Additionally, because Ts65Dn mice show degeneration of basal forebrain cholinergic neurons\(^4\),\(^{19}\),\(^{29}\) that correlates with their cognitive decline\(^{29}\), and the fact that deficits in cholinergic modulation in Ts65Dn mice\(^{19}\),\(^{29}\)\(^{-31}\) are likely to affect olfactory learning\(^32\), we hypothesized that the administration of an acetylcholinesterase inhibitor drug galantamine hydrobromide would ameliorate their olfactory learning behavior. We observed that trisomic mice exhibited significant deficits in olfactory based learning compared to disomic litterate controls and that this deficit could be rescued by galantamine treatment. Collectively, our study indicates that olfactory learning performance can be a sensitive tool for evaluating deficits in associative learning in mouse models of DS and that galantamine has therapeutic potential for improving cognition in this syndrome.

Results

**Trisomic Ts65Dn mice perform worse than controls in olfactory learning.** Ten disomic and ten trisomic mice were tested on the olfactory learning tasks. Figures 1 A and B show representative behavior of individual disomic and trisomic mice during the first and second test-days in the odor detection task (Task A, citral vs. mineral oil).

Figures 1 C and D show the average percent correct for the two training days on each odor pair. A repeated measures ANOVA (genotype*odor-pair*sex) indicates a significant effect of the genotype (F\(_{5,9.6}\) = 9.6; p = 0.007), as well as an overall significant improvement from day 1 to day 2 (F\(_{5,7.1}\) = 7.1; p = 0.018). There was a significant odor pair*sex interaction (F\(_{5,6.8}\) = 6.8; p = 0.02). Post-hoc analyses reveal that performance of disomic mice improved significantly from day 1 to day 2 (58.1% to 73.5%, p = 0.004, Tukey’s HSD). This was not the case for trisomics (57.5% to 61.7%, p = 0.75). Performance on Day 2 alone was significantly better for disomics than trisomics (p = 0.034).

Collectively these results indicate that trisomics exhibit impaired learning when compared to their disomic counterparts. To ensure that the difference in learning did not stem from initial behavioral differences when beginning the task, we performed a detailed behavioral analysis on the first 5 blocks of the first day of learning (citral vs. Mineral Oil). There was no significant difference in the number of licks between disomic and trisomic mice (on rewarded, unrewarded trials or both; Supplemental Figure 1, Mann-Whitney U test: U = 9, p = 0.46). This indicates that subsequent differences in learning were not due to differences in the initial sampling strategy, or to differential emotional responses to the testing apparatus.

**Galantamine treatment elicits better performance in olfactory learning in trisomic mice.** We tested the effect of a chronic treatment with galantamine or saline (shams) on the learning performance of disomic and trisomic male mice (Fig. 2). The performance of Ts65Dn mice was significantly improved by chronic injections of galantamine. Repeated measures ANOVA (treatment*odor-pair*day) reveals a significant effect of the treatment (F\(_{5,5.1}\) = 5.1; p = 0.038), day (F\(_{5,5.1}\) = 5.1; p = 0.02), and interaction day*odor-pair (F\(_{5,6.6}\) = 6.6; p = 0.02). The improvement from D1 to D2 was only evident for the citral vs. mineral oil task (HSD Tukey post-Hoc; p = 0.007). While galantamine improved the overall performance (Tukey post-Hoc test p = 0.038), the effect could not be narrowed down to one odor pair. In spite of an apparent increase in performance, galantamine had no significant effect on disomic mice (repeated measures ANOVA (treatment*odor-pair*day; treatment effect: p = 0.121). Performance increased

---

Figure 1 | A and B. Examples of olfactory learning behavior of trisomic and disomic mice exposed to odor pairs A and B. Bold lines represent disomic mice, and dashed lines the trisomic mice. (A) Representative responses of a single trisomic (dashed line with circle markers) and disomic mice (continuous line with square markers) on the first test-day on odor pair A. (B) Same as A, but for the second test-day. (C) Mean correct responses for all blocks within each section on the first and second days for odor pair A. (D) Same as C, but for odor pair B. Note that these mice do not achieve learning in day 1. This indicates that mice of the C3H background take two days in achieving learning in this task. Mean (circle or square markers) and standard error bars are shown for each case. Significant differences are marked with one (P<0.05) or two asterisks (P<0.01). The y-axis shows the percent of correct responses.
from D1 to D2 (post-Hoc Tukey: p = 0.002), for both treatment groups (saline p = 0.035, galantamine p = 0.009).

**Discussion**

The observed olfactory learning performances of trisomic and disomic mice in the olfactometer (Fig. 1) constitutes the first demonstration that olfactory-based associative learning is negatively affected in Ts65Dn mice. The poor performance in the associative learning task, combined with documented deficits in spatial cognition, strongly support a widespread effect of this trisomy on adaptive behaviors. This wide array of cognitive and sensory deficits validate the Ts65Dn mouse as a valid model of Down Syndrome. The deficit in olfactory-based associative learning is likely due to both deficits in learning and odor perception. These deficits are well-documented in human: mild to moderate mental retardation is evident in verbal and mental performance and olfactory deficits.

The presence of a third copy and presumed overexpression of genes from Chr 21 in humans with DS, and Chr 16 in Ts65Dn mouse result in a complex perturbation of multiple processes involved in neurological development and function. Many genes expressing olfactory membrane receptors are located on Chr 21 in humans and Chr 16-17 in mice, but the neurological effects of the presumed overexpression of these olfactory genes is not known. On one hand, olfactory receptor proteins are expressed from a single allele, and an overrepresentation of the olfactory receptor genes is unlikely to lead to an overexpression of olfactory receptor proteins. However it is unknown if this overrepresentation of the olfactory receptor genes could generate a down-regulation effect on the expression of certain olfactory receptor proteins that could decrease the sensitivity of the olfactory system to certain odorants. Conversely, changes in expression of other genes such as ApoE epsilon 4 could mediate an olfactory associative learning deficit.

Previous work has provided evidence of olfactory impairment in patients with DS and a role for cholinergic neurodegeneration in this aspect of DS pathology is supported by the observation that olfactory loss is also a common facet of Alzheimer’s disease. It is difficult to dissociate the olfactory effects that could be caused by the overrepresentation of olfactory receptor genes from those caused by the neural degeneration associated with the early onset of Alzheimer’s disease. This is a limitation of our approach, since the olfactometer cannot separate learning and olfactory impairment. Thus, we do not know how changes in protein expression induced by DS affect olfactory learning and further studies will be required to investigate these questions.

Another neurological consequence associated to the overexpression of genes in Ts65Dn mice is the diminished number of cholinergic neurons on the basal forebrain, which likely is one of the main causes of their learning deficits, and could underlie olfactory deficits.

**Figure 2** | Olfactory learning behavior of odor pairs A and B by disomic and trisomic mice on chronic treatment with galantamine or saline. Olfactory learning behavior of disomic (continuous lines) and trisomic (dashed lines) mice under chronic treatment with galantamine (square markers) or saline (circle markers), and exposed to odor pairs A and B. (A) Mean number of correct responses of disomic mice on galantamine and saline for all blocks on odor pair A. (B) Same as A, but for trisomic mice. (C) Same as A, but for odor pair B. (D) Same as B, but for odor pair B. Mean (circle or square markers) and standard error bars are shown for each case. Significant differences are marked with one (P < 0.05) or two asterisks (P < 0.01). The y-axis shows the percent of correct responses.
The cholinergic neurons on the basal forebrain innervate the cortical 
region in a relatively widespread manner47–50, and the acetylcholine 
release from these basal forebrain cholinergic neurons modulates the 
cortex neurons and consequently the cerebral cortex51–52. It is known 
that the manifestations of dementia in DS have been associated with a 
frontal lobe dysfunction53, which could be associated with the reduced 
number of cholinergic neurons54. In addition, decreased number of 
cholinergic neurons in the horizontal diagonal band of Broca in the 
basal forebrain would result in decreased projection of axons to the 
olfactory bulb thereby affecting olfactory processing51–53.

If the deficit in neural activity is due to decreased Ach neuron 
expression, it should be compensated by using pharmacological acti-
ators of cholinergic neurons54,55, like galantamine that boosts Ach 
responses in the neural terminals and nicotinic Ach Receptors56,57. 
In this way, the galantamine activation of cholinergic neuron in the 
basal forebrain that project to cortical neurons and olfactory areas 
could conceivably activate the cholinergic neurons and possibly res-
ue some of the neurological and behavioral deficits associated with 
DS. This possibility is consistent with previous work that has shown 
that perinatal dietary supplementation with choline acts to signifi-
cantly improve cognition and emotion regulation in the Ts65Dn 
mouse model58.

In the present study we observed that the galantamine treatment 
enabled trisomic mice to reach a performance level comparable with 
that of disomic mice (Fig. 2). A significant improvement in the 
percent of correct choices occurred in disomic and trisomic mice 
under chronic treatment with galantamine. Galantamine treatment 
proved the performance of trisomic mice in both tasks, while it only 
helped the performance of disomic mice on the most difficult of 
them (task B). An explanation for the lack of effect of galantamine 
on the performance of disomic mice on odor pair A comes from the 
fact that they already achieved high scores on this task leaving little 
scope for improvement. Thus, galantamine an acetylcholinesterase 
inhibitor and an agonist of nicotinic receptors elicits improved 
performance in an olfactory learning task in trisomic Ts65Dn mice. 
Interestingly, in the past no improvement in behavioral performance in 
the Morris Water Maze was found in these mice after treatment 
with the acetylcholine esterase inhibitor donepezil59. In the future it 
makes sense to test galantamine and donepezil in parallel experi-
ments in olfactory learning and MWM. Finally, in spite of the fact 
that we cannot dissociate totally olfactory deficits from learning 
deficits at a behavioral level, the positive action of galantamine in 
our mice taken together with evidence from literature showing that 
non-olfactory learning deficits in Ts65Dn are linked to a diminished 
number of cholinergic neurons in the basal forebrain, reinforce the 

Supplementary Information

Methods

Animals. The Ts65Dn subjects were either obtained directly from The Jackson 
Laboratory (Bar Harbor, ME)(B6EiC3Sn a/A-Tc(T17<16>~65Dn)) or by mating 
female carriers of the partial trisomy to hybrid males (C57Bl/6 Iecher x C3H/HeSnF1) 
obtained from The Jackson Laboratory. They were genotyped by fluorescence 
in situ hybridization (FISH) using a probe for the centromere of mouse Chr 16 
and Chr 1760,61.

In this study we used a total of 28 trisomic Ts65Dn mice and 26 disomic littermates. 
45 male and 9 female mice between 3 and 6 months were used. 10 trisomic and 
10 disomic naive mice were used for the characterization of the olfactory learning 
behavior in the go-no go task. Specifically for testing the effect of galantamine on 
mouse olfactory behavior, a group of 6 disomics was treated with daily intranasal (i.p.) 
injections of galantamine and another group of 8 disomics was treated with daily 
i.p. injections of saline vehicle. In the same way, a group of 9 trisomic Ts65Dn mice 
was treated with saline vehicle and another 9 with galantamine. The same 34 mice 
used for testing the effect of saline and galantamine on the go-no-go test were also 
used after an oral hidden peanut butter finding test. All experiments were approved by 
the University of Colorado Anschutz Medical Center institutional animal care 
and use committee and were performed according to the NIH standards for animal 
care and use.

Operant conditioning behavior. We used the behavioral go-no go olfactory learning 
methods61 detailed briefly as follows. In order to elicit motivation to obtain 
water reward, animals were water-deprived to 80-85% of original body weight. Then mice 
were trained during 3 days to poke in an odor sampling port and then respond by 
licking the water delivery port in the presence of 10% citral in mineral oil to receive a 
drop of water. Each trial is initiated by the mouse inserting its head in the odor-
sampling port and is followed by a 2.5 sec delivery of the odor. Reinforcement is 
delivered if the mouse licks on the water-delivery tube at least once in each of the last 
four 0.5 sec intervals of the 2.5 sec odor delivery period.

Next, the mice learned to respond to the S+ (rewarded) odor and not to the 
S- (unrewarded) odor. S+ and S- trials are presented in a pseudo-randdom order with 
the following restrictions: i) equal number of rewarded and unrewarded trials in each 
block of 20 trials and ii) no more than 3 of the same trials in a row. Each session has 
a maximum of 10 blocks (200 trials). The session was terminated either when the 
animal completed 10 blocks or when the animal became satiated and started initi-
tiating trials for over eight minutes. To determine the percentage of correct responses 
in each block of 20 trials the following formula was used:

\[
PCR = \frac{HITS+CR}{20}
\]

where PCR are the percent of correct responses, HITS are rewarded trials in which the 
subject successfully obtained the reward, and CR are correct rejections - where the 
animal restrained from licking on an unrewarded trial.

Olfactory stimuli for the go-no go task. Each subject was tested in two different 
learning tasks:

Task A (odor detection): Citral 10% (S+, rewarded), Mineral oil (S-, unrewarded) 
Task B (odor discrimination): 2-Heptanone 1% (S+); 3-Heptanone 1% (S-)

Task A is a simple discrimination task that used mineral oil alone, a diluent with 
relatively weak odor as the unrewarded stimulus62. A large difference in odor quality 
was used in task A (strong citral vs. weak odor mineral oil) because a strong difference 
in odor quality is necessary to when mice first learn to perform in the odor dis-

Supplementary Information

Testing the effect of treatment with galantamine on go-no go olfactory learning 
behavior. We tested the effects of galantamine treatment on olfactory learning 
behavior in a separate group of naive mice. During days when the mice were 
undergoing olfactory learning in the go-no go task animals were injected intraperi-
tonally daily with 3 μg/g (drug/body weight) of galantamine hydrobromide (Tocris 
Cookson Inc, Catalog number 0686) diluted in sterile saline, and tested 4 hours after 
the injection63,64. Daily chronic injections of galantamine hydrobromide started 
two days after the baseline recording period. The presence of S+ only, and continued 
throughout the go-no-go test in the presence of S+ and S-. Trisomics as well as 
disomic mice were split into two groups, one receiving the galantamine, the other 
receiving sham injections of sterile saline alone. Because performance in the 
olfactometer tends to improve with time, it is not possible to compare the perform-
ance of the same individual on different treatments. The effect of galantamine was 
therefore assessed in independent groups. The total length of treatment with 
galantamine was 10 days.

Hidden peanut butter finding test. A simple digging test was used as an independent 
test of mouse olfactory ability in a task to find an odor reward hidden in the cage65. 
Mice of all 4 groups (both genotypes, both treatments) were given peanut butter, an 
appetitive stimulus they were allowed to eat, on the day before to the test day. Then, 
on the next day, mice were placed in the middle of a clean cage with a Petri dish with
peanut butter reward hidden under the 5 cm thick bedding, and we recorded the latency to dig and find the peanut butter reward.

**Statistics.** The percent of correct responses per block were obtained for each animal, and then the mean and standard error of the mean (SEM) were calculated for each group. Statistical analyses for significance of differences in odor learning were performed using the Statistica software (StatSoft, Inc.) and the Matlab Statistics Toolbox (The MathWorks, Inc., Natick, MA). The mean percent correct for all blocks per session (MPC) for each odor pair was analyzed and is shown in the figures. Groups were compared using unpaired t tests and repeated measures analysis of variance (ANOVA), using performance on day 1 and day 2 for each odor pair as the repeated measures. Tukey’s Post-Hoc tests were then used, where p<0.05 was considered statistically significant.

1. Rösen, N. J. & Patterson, D. Down’s syndrome. *Lancet* 363, 1281–1289 (2003).
2. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. *Behavioral genetics of Down syndrome: from genomics to pathophysiology*. Nat Rev Genet 5, 725–738 (2004).
3. Hix, R. F., Botting, N. & Conti-Ramsden, G. Short-term memory and vocabulary development in children with Down syndrome and children with specific language impairment. *Dev Med Child Neurol* 47, 532–538 (2005).
4. Hunter, C. L., Bimonte, H. A. & Granholm, A. C. Behavioral comparison of 4 and 6 month-old T65Dn mice: age-related impairments in working and reference memory. *Behavioural brain research* 138, 121–131 (2003).
5. Benavides-Piccione, R. et al. On dendrites in Down syndrome and DS murine models: a spiny way to learn. *Progress in neurobiology* 74, 111–126 (2004).
6. Schneider, C. et al. Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. *Neurosci Lett* 222, 183–186 (1997).
7. Wegiel, J. et al. Neuronal loss and beta-amyloid removal in the amygdala of people with Down syndrome. *Neurobiology of aging* 20, 259–269 (1999).
8. Tessarollo, L. Brain disorders getting ‘Down’ to the gene. *Nature neuroscience* 13, 909–910 (2010).
9. Wang, B. Cognitive deficits in Down syndrome: narrowing ‘Down’ to Olig1 and Olig2. *Clin Genet* 79, 47–48 (2011).
10. Gardiner, K. et al. Down syndrome: from understanding the neurobiology to therapy. *The journal of neuroscience: the official journal of the Society for Neuroscience* 30, 14943–14945 (2010).
11. Davison, M. T., Schmidt, C. & Aksenov, E. C. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. *Prog Clin Biol Res* 360, 263–280 (1990).
12. Chakrabarti, L. et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. *Nature neuroscience* 13, 927–934 (2010).
13. Reeves, R. H. et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. *Nature genetics* 11, 177–184 (1995).
14. Seregaa, Z., Roubertoux, P. L., Jannin, M. & Soumier-Mourat, B. Mouse models of cognitive disorders in trisomy 21: a review. *Behavioral genetics* 36, 387–404 (2006).
15. Escorihuela, R. M. et al. Impaired short- and long-term memory in T65Dn mice, a model for Down syndrome. *Neuropsi Let* 247, 171–174 (1998).
16. Klein, S. L. et al. Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (T65Dn) mice. *Physiology & behavior* 60, 1159–1164 (1996).
17. Hyde, L. A. & Crnic, L. S. Age-related deficits in context discrimination learning in T65Dn mice that model Down syndrome and Alzheimer’s disease. *Behavioral neuroscience* 113, 226–246 (2001).
18. Hyde, L. A., Frisoni, D. F. & Crnic, L. S. T65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. *Behavioural brain research* 118, 53–60 (2001).
19. Granholm, A. C., Sanders, L. A. & Crnic, L. S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down syndrome. *Experimental neurobiology* 161, 647–663 (2000).
20. Costa, A. C., Walsh, K. & Davison, M. T. Motor dysfunction in a mouse model for Down syndrome. *Physiology & behavior* 68, 211–220 (1999).
21. Galdzicki, Z. & Siray, R. J. Understanding mental retardation in Down’s syndrome using trisomy 16 mouse models. *Genes, brain, and behavior* 14, 167–178 (2003).
22. Wenger, G. R., Schmidt, C. & Davison, M. T. Operant conditioning in the T65Dn mouse: learning. *Behavior genetics* 34, 105–119 (2004).
23. Cossouls-Read, M. E. & Crnic, L. S. Behavioral assessment of the T65Dn mouse, a model for Down syndrome: altered behavior in the elevated plus maze and open field test. *J Neurosci* 16, 7–13 (1996).
24. Costa, A. C., Stasko, M. R., Schmidt, C. & Davison, M. T. Behavioral validation of the T65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). *Behavioural brain research* 206, 52–62 (2010).
25. Olsen, L. E. et al. Trisomy for the Down syndrome ‘critical region’ is necessary but not sufficient for brain phenotypes of trisomic mice. *Hum Mol Genet* 16, 774–782 (2007).
26. Turner, C. A. et al. Spontaneous stereotypy in an animal model of Down syndrome: T65Dn mice. *Behavior genetics* 31, 393–400 (2001).
Acknowledgements
We are grateful for funding of this project by the Anna and John Sie Foundation to DR and KNM. DR gratefully acknowledges support from NIH grants DC008855 and DC04657. KNM gratefully acknowledges financial support from NICHD grant HD045224. FS thanks Michael Hall for build the olfactometers hardware.

Author contributions
FS helped generate an experimental design, assembled and troubleshooted the olfactometers, performed a subset of the experiments, plotted the main figures, helped analyzing the data and writing the manuscript. NB performed statistical analysis of the data and helped write the manuscript. MB performed a subset of the experiments. KM helped with the experimental design, genotyping and writing the manuscript and DR helped develop an experimental design, troubleshoot the olfactometer, analysis and writing of the manuscript.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interests.

License: This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

How to cite this article: Simoes de Souza, F.M., Busquet, N., Blatner, M., Maclean, K.N. & Restrepo, D. Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome. Sci. Rep. 1, 137; DOI:10.1038/srep00137 (2011).